Drug company Ajanta Pharma today reported a 75.95 per cent increase in net profit at Rs 32.57 crore for the third quarter ended December 31, 2012, mainly on robust sales.
The company had posted a net profit of Rs 18.51 crore in the corresponding period previous fiscal.
Net sales rose to Rs 225.68 for the quarter under consideration from Rs 164.52 crore in the same period last fiscal, Ajanta Pharma said in a BSE filing.
“The company recently received market authorisation in the UK for Slidenafil tablets of strength 50 mg and 100 mg. The company expects to launch the same in the UK when it goes off patent in June 2013,” Ajanta Pharma said.
Shares of Ajanta Pharma were trading at Rs 490.65 apiece in the afternoon trade on the BSE, 19.99 per cent rise from their previous close.